Crossmark

A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy

Crossref DOI link: https://doi.org/10.1007/s00109-020-01881-3

Published Online: 2020-01-29

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nicolini, Andrea

Rossi, Giuseppe

Ferrari, Paola

Morganti, Riccardo

Carpi, Angelo
License Information

Text and Data Mining valid from 2020-01-29

Version of Record valid from 2020-01-29
More Information

Article History

Received: 30 April 2019

Revised: 17 January 2020

Accepted: 21 January 2020

First Online: 29 January 2020

Compliance with ethical standards

:

: All patients gave witnessed written informed consent and the study was approved by the Council of the Department of Internal Medicine of Pisa University. The study was performed in accordance with the Declaration of Helsinki.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below